Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study - Hurvitz SA; Bardia A; Quiroga V; Park YH; Blancas I; Alonso-Romero JL; Vasiliev A; Adamchuk H; Salgado M; Yardley DA; Berzoy O; Zamora-Auñón P; et al. (2023)